Tenet divestment continues by scaling back Texas joint venture

Tenet Healthcare has reached an agreement with Baylor Scott & White Health to restructure their two-year-old joint venture involving five North Texas hospitals.

One facility (Baylor Scott & White Medical Center-Garland) will be closed on March 1, while another (the 218-bed Baylor White and Scott Medical Center-White Rock) will be sold to Manhattan Beach, California-based Pipeline Health.

The new arrangement concerned the three remaining facilities in the venture. For two hospitals (Baylor Scott & White–Centennial and Baylor Scott & White–Lake Pointe), Tenet’s minority interest will be acquired by Baylor Scott & White, which will also take operation of the facilities. Baylor Scott & White – Sunnyvale will be absorbed into a separate joint venture called Texas Health Ventures Group run by Baylor Scott & White along with Tenet’s United Surgical Partners International subsidiary.

The two companies expected the transactions to be completed in the spring of 2018.

The restructuring fits with Tenet’s moves to sell off assets and address its $15 billion in debt. At one point it considered selling itself off, but after the early departure of CEO and chairman Trevor Fetter, the company has focused on reducing costs. Tenet is aiming to cut $250 million over the next year and making additional divestments, such as publicly announcing its seeking a buyer for its Conifer Health Solutions business services subsidiary.

Before his departure, Fetter had said sales of eight U.S. hospitals and its nine United Kingdom hospitals and clinics would yield $1 billion for the company. The U.S. divesture has included a $170 million deal to sell two Philadelphia facilities to Paladin Healthcare, unloading MacNeal Hospital in Berywn, Illinois. and seeking a buyer for three more hospitals in the Chicago area.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.